NSE ScannerHospitals & Diagnostics · Medical/Nursing Services · NSE: NIDAN · data 2026-11-01
Nidan Laboratories and Healthcare Limited
In plain words
Price: 47.8% below its 52-week high of ₹24.9.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹26 cr |
| Net profit (last 12 months) | ₹2 cr |
| Sales growth, 3 years (yearly) | 1.7% |
| Profit growth, 3 years (yearly) | -24.8% |
At a glance
P/E 12.0, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 2.2%, ROCE 4.0%, operating margin 11.5%: how much profit it earns on the money it uses.
Debt/equity 0.16, Profit growth -24.8% and sales growth 1.7% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (2.2%).
- Profit fell 24.8% a year over 3 years.
- Slow sales growth (1.7% a year over 3 years).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions
- Delivery vs usual 0/30: No stored daily delivery history for this stock (0 points).
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Nidan Laboratories and Healthcare Limited debt-free?
Its latest reported debt-to-equity ratio is 0.16.
What is Nidan Laboratories and Healthcare Limited's P/E ratio?
About 12, based on the last 12 months' earnings and a price of ₹13 (data 2026-11-01).
What is the 52-week high and low of Nidan Laboratories and Healthcare Limited?
The 52-week high is ₹24.9 and the 52-week low is ₹11.5.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Nidan Laboratories and Healthcare Limited | ₹13 | ₹18 cr | 12 | — | 2.2% | 4% | 0.16 | -33.3% |
| CHANDAN HEALTHCARE LIMITED | ₹235 | ₹575 cr | — | — | 18.4% | 23.4% | 0.31 | -33.8% |
| Rays of Belief Limited | ₹245.16 | ₹513 cr | — | — | — | — | — | +2.6% |
| Pramodini Medicare Limited | ₹106.6 | ₹235 cr | — | — | — | — | — | -11.2% |
| Lotus Eye Hospital And Institute Ltd | ₹109.15 | ₹221 cr | 1,520.2 | — | 0.1% | -0.3% | 0.26 | -9.0% |
| Vaidya Sane Ayurved Laboratories Limited | ₹136 | ₹143 cr | 15.9 | 1.6 | 12% | 12% | 0.03 | -48.7% |
Compare NIDAN with CHANDAN in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open NIDAN in NSE Scanner →